{
  "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
  "docSlug": "560176b410a72a6b2e67af5dd2a20758",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 33,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "comparison_table",
  "function": "cite_precedent",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a 'Case Study' to validate the company's own strategy of combination therapy.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/23",
  "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
  "deckJsonHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56.json",
  "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.64,
        "y": 0.24
      },
      "kind": "list",
      "text": "Successful combination strategies in neurology: Alzheimer's (Donepezil + Memantine), Parkinson's (Entacapone + levodopa/carbidopa), ALS (Sodium Phenybuterate + Taurursodiol), SMA (Onasemnogene + Nusinersen), Epilepsy (Lamotrigine + Valproate/Carbamazepine)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ca5dea6-e761-45a3-bcf0-a76ea67b28b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Case Study: Amylyx (NASDAQ: AMLX)\nMarket Cap: ~ $1 B (December 2023)\nDrug: ALS Combination Therapy of generic + supplement\nPrice: $158,000/ year\nEstimated 2026 Sales: $1.1B/ year\nThe FDA approved Amylyx's drug, AMX0035 (Relyvrio), in September 2022 after Phase 2 clinical trial attenuated diseases progression (ALSFRS-R) by 25% when compared to placebo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d7cab10-ed9b-48cb-b8a5-6b34a41e565f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "1 SVB Securities analyst Marc Goodman\n2 Relyvrio is a registered trademark of Amylyx\n3 Study results are not for comparison",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30420459-e2bb-4d51-9aca-411df659b09a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "Proven Success of Combined Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a022ce76-bdc9-4411-abfc-807a2e17bebb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "argument-from-analogy",
      "slug": null,
      "matchId": "2c780ace-ad23-417c-93ad-c973482ff8ca",
      "evidence": "Uses Amylyx case study to validate the efficacy and market potential of the company's own combination therapy approach.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 6,
      "beatId": "34d973c9-414c-4e7d-9b2b-216172775550",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}